Beijing: China granted the first patent of invention to a vaccine developed jointly through the biopharmaceutical company CanSino Biologics Inc in the country, which experts say demonstrates the originality and creativity of the vaccine.
According to a Global Times report, the vaccine is a recombinant adenovirus vaccine called Ad5-nCoV developed jointly through CanSino with a team led by the Chinese army infectious disease Chen Wei.
“The grant of the patent showed the effectiveness and protection of the vaccine, and convincingly demonstrated ownership of its intellectual property rights (IPRs),” CanSino said on a Sunday.
An officially granted patent would build confidence in China’s COVID-19 vaccines, “particularly in the foreign market.”
“The United States has been accusing China of seeking to borrow new knowledge about coronavirus on remedies and vaccines without providing really extensive evidence,” the report said.
According to CanSino, they filed a patent application with the National Intellectual Property Administration on March 18, 3 days after starting a clinical trial with the applicant and receiving approval on August 11.
The phase III trial of the vaccine “to be conducted is progressing smoothly,” the company said in the statement.
CanSino has signed agreements with Mexico to conduct complex clinical trials of COVID-19 vaccines.
Saudi fitness also announced on August 9 that it would cooperate with phase III clinical trials of the vaccine, recruiting some 5,000 participants.
CanSino is also in talks with Russia, Brazil and Chile to launch a III test on Ad5-nCOV.
Meanwhile, Russia has begun production of the first batch of vaccines against COVID-19, its health ministry said in a statement over the weekend.
The world’s first recorded vaccine to oppose the new coronavirus announced by President Vladimir Putin last week in an online assembly with government officials.
The third phase of studies on the world’s first recorded vaccine opposing the new coronavirus, called Sputnik V, can begin in 7 to 10 days.
According to the Tass news agency, tens of thousands more people are expected to participate in these studies of the vaccine created through the Gamaleya Institute for Scientific Research in Epidemiology and Microbiology of the Russian Ministry of Health.
The Sputnik V vaccine, named after the area satellite introduced through Moscow in 1957, created through the Gamaleya Institute for Scientific Research in Epidemiology and Microbiology, together with the Russian Direct Investment Fund.
Dear reader,
This segment is about life in the United Arab Emirates and data you cannot live without.
Sign up to read and complete gulfnews.com